Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System

Launched by FONDAZIONE DON CARLO GNOCCHI ONLUS · Aug 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how effective robotic treatment is for people with neurological diseases, such as Multiple Sclerosis, Stroke, Parkinson's Disease, and Acquired Brain Injury. The goal is to create a model that helps predict which patients may benefit the most from this type of treatment using a special robotic system called G-EO. By understanding who responds best, doctors can provide more tailored care for their patients.

To participate in this trial, individuals must be at least 18 years old and able to walk at least 10 meters, even if they need some help. They should be able to sit without support for 30 seconds and stand upright for 7 minutes. Participants will need to attend at least 10 sessions of the robotic treatment, with a minimum of 2 sessions each week. However, those with severe joint issues, certain medical conditions that affect walking, or skin problems in the areas where the device makes contact won't be able to join. If you are eligible, you can expect to receive robotic therapy that aims to improve your walking ability while contributing to important research on the treatment's effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of Multiple Sclerosis, Parkinson Disease, Stroke or acquired brain injury
• • Minimum number of sessions: 10 sessions with the GEO system
• • Minimum frequency of sessions: 2 per week
• • Age ≥ 18 years
• • Ability to walk for at least 10 meters, also with aid
• • Indication of robotic treatment in the therapeutic plan
• • Body size suitable for the robotic device
• • ability to maintain verticality for 7 minutes;
• • ability to maintain the sitting position without support for 30 seconds;
• Exclusion Criteria:
• • severe limitations of articular range of motion;
• • medical problems compromising walking (e.g. fractures, pain, severe osteoporosis or severe spasticity);
• • Presence of skin lesions in the areas of contact with the device;
• • Presence of seizures that may be triggered by the use of the G-EO system.